These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 29463526)

  • 21. Moxifloxacin population pharmacokinetics in patients with pulmonary tuberculosis and the effect of intermittent high-dose rifapentine.
    Zvada SP; Denti P; Geldenhuys H; Meredith S; van As D; Hatherill M; Hanekom W; Wiesner L; Simonsson US; Jindani A; Harrison T; McIlleron HM
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4471-3. PubMed ID: 22585223
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Population Pharmacokinetic Analysis Shows that Arylacetamide Deacetylase (AADAC) Gene Polymorphism and HIV Infection Affect the Exposure of Rifapentine.
    Francis J; Zvada SP; Denti P; Hatherill M; Charalambous S; Mungofa S; Dawson R; Dorman S; Gupte N; Wiesner L; Jindani A; Harrison TS; Olagunju A; Egan D; Owen A; McIlleron HM
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670438
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SLCO1B1 and SLC10A1 polymorphism and plasma rifampin concentrations in patients with co-morbidity tuberculosis-diabetes mellitus in Baja California, Mexico.
    Perea-Jacobo R; Muñiz-Salazar R; Laniado-Laborín R; Zenteno-Cuevas R; Cabello-Pasini A; Ochoa-Terán A; Radilla-Chávez P
    Tuberculosis (Edinb); 2022 Sep; 136():102248. PubMed ID: 36055153
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Shortened treatment regimens versus the standard regimen for drug-sensitive pulmonary tuberculosis.
    Grace AG; Mittal A; Jain S; Tripathy JP; Satyanarayana S; Tharyan P; Kirubakaran R
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012918. PubMed ID: 31828771
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics and response to pravastatin in paediatric patients with familial hypercholesterolaemia and in paediatric cardiac transplant recipients in relation to polymorphisms of the SLCO1B1 and ABCB1 genes.
    Hedman M; Antikainen M; Holmberg C; Neuvonen M; Eichelbaum M; Kivistö KT; Neuvonen PJ; Niemi M
    Br J Clin Pharmacol; 2006 Jun; 61(6):706-15. PubMed ID: 16722833
    [TBL] [Abstract][Full Text] [Related]  

  • 26.
    Mthiyane T; Millard J; Adamson J; Balakrishna Y; Connolly C; Owen A; Rustomjee R; Dheda K; McIlleron H; Pym AS
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31964788
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis.
    Burman WJ; Goldberg S; Johnson JL; Muzanye G; Engle M; Mosher AW; Choudhri S; Daley CL; Munsiff SS; Zhao Z; Vernon A; Chaisson RE
    Am J Respir Crit Care Med; 2006 Aug; 174(3):331-8. PubMed ID: 16675781
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics.
    Niemi M; Backman JT; Kajosaari LI; Leathart JB; Neuvonen M; Daly AK; Eichelbaum M; Kivistö KT; Neuvonen PJ
    Clin Pharmacol Ther; 2005 Jun; 77(6):468-78. PubMed ID: 15961978
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increased Doses Lead to Higher Drug Exposures of Levofloxacin for Treatment of Tuberculosis.
    Peloquin CA; Phillips PPJ; Mitnick CD; Eisenach K; Patientia RF; Lecca L; Gotuzzo E; Gandhi NR; Butler D; Diacon AH; Martel B; Santillan J; Hunt KR; Vargas D; von Groote-Bidlingmaier F; Seas C; Dianis N; Moreno-Martinez A; Kaur P; Horsburgh CR
    Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30012767
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial.
    Diacon AH; Dawson R; von Groote-Bidlingmaier F; Symons G; Venter A; Donald PR; van Niekerk C; Everitt D; Winter H; Becker P; Mendel CM; Spigelman MK
    Lancet; 2012 Sep; 380(9846):986-93. PubMed ID: 22828481
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacogenetic Study of Drugs Affecting Mycobacterium tuberculosis.
    Shabani S; Farnia P; Ghanavi J; Velayati AA; Farnia P
    Int J Mycobacteriol; 2024 Apr; 13(2):206-212. PubMed ID: 38916393
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Moxifloxacin plus standard first-line therapy in the treatment of pulmonary tuberculosis: A meta-analysis.
    Chen Z; Liang JQ; Wang JH; Feng SS; Zhang GY
    Tuberculosis (Edinb); 2015 Jul; 95(4):490-6. PubMed ID: 25964137
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Concentration-Dependent Antagonism and Culture Conversion in Pulmonary Tuberculosis.
    Rockwood N; Pasipanodya JG; Denti P; Sirgel F; Lesosky M; Gumbo T; Meintjes G; McIlleron H; Wilkinson RJ
    Clin Infect Dis; 2017 May; 64(10):1350-1359. PubMed ID: 28205671
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synergistic activities of clofazimine with moxifloxacin or capreomycin against Mycobacterium tuberculosis in China.
    Li G; Xu Z; Jiang Y; Liu H; Zhao LL; Li M; Xu D; Zhao X; Liu Z; Wang R; Wan K
    Int J Antimicrob Agents; 2019 Nov; 54(5):642-646. PubMed ID: 31200023
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early Bactericidal Activity Trial of Nitazoxanide for Pulmonary Tuberculosis.
    Walsh KF; McAulay K; Lee MH; Vilbrun SC; Mathurin L; Jean Francois D; Zimmerman M; Kaya F; Zhang N; Saito K; Ocheretina O; Savic R; Dartois V; Johnson WD; Pape JW; Nathan C; Fitzgerald DW
    Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32071052
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis.
    Jindani A; Harrison TS; Nunn AJ; Phillips PP; Churchyard GJ; Charalambous S; Hatherill M; Geldenhuys H; McIlleron HM; Zvada SP; Mungofa S; Shah NA; Zizhou S; Magweta L; Shepherd J; Nyirenda S; van Dijk JH; Clouting HE; Coleman D; Bateson AL; McHugh TD; Butcher PD; Mitchison DA;
    N Engl J Med; 2014 Oct; 371(17):1599-608. PubMed ID: 25337749
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Moxifloxacin Replacement in Contemporary Tuberculosis Drug Regimens Is Ineffective against Persistent Mycobacterium tuberculosis in the Cornell Mouse Model.
    Liu Y; Pertinez H; Davies GR; Gillespie SH; Coates AR; Hu Y
    Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29661869
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of moxifloxacin on QTc interval in adults with pulmonary tuberculosis.
    Nair D; Velayutham B; Marimuthu M; Navaneethapandian PGD; Chinnaiyan P; Jawahar MS; Swaminathan S
    Natl Med J India; 2018; 31(1):58-59. PubMed ID: 30348931
    [No Abstract]   [Full Text] [Related]  

  • 39. Moxifloxacin target site concentrations in patients with pulmonary TB utilizing microdialysis: a clinical pharmacokinetic study.
    Heinrichs MT; Vashakidze S; Nikolaishvili K; Sabulua I; Tukvadze N; Bablishvili N; Gogishvili S; Little BP; Bernheim A; Guarner J; Peloquin CA; Blumberg HM; Derendorf H; Kempker RR
    J Antimicrob Chemother; 2018 Feb; 73(2):477-483. PubMed ID: 29186509
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Limited Effect of Later-Generation Fluoroquinolones in the Treatment of Ofloxacin-Resistant and Moxifloxacin-Susceptible Multidrug-Resistant Tuberculosis.
    Lee H; Ahn S; Hwang NY; Jeon K; Kwon OJ; Huh HJ; Lee NY; Kim CK; Koh WJ
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29203478
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.